[{"address1": "535 W 24th Street", "address2": "5th Floor", "city": "New York", "state": "NY", "zip": "10011", "country": "United States", "phone": "855 508 3568", "website": "https://www.neurogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel L. McMinn Ph.D.", "age": 51, "title": "Founder, Executive Chair & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 676542, "exercisedValue": 0, "unexercisedValue": 203486}, {"maxAge": 1, "name": "Ms. Christine Mikail Cvijic J.D.", "age": 46, "title": "President, CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 623289, "exercisedValue": 0, "unexercisedValue": 658819}, {"maxAge": 1, "name": "Dr. Stuart  Cobb Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 478807, "exercisedValue": 0, "unexercisedValue": 338906}, {"maxAge": 1, "name": "Ms. Donna M. Cochener-Metcalfe J.D.", "age": 49, "title": "Senior VP & General Counsel", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Effie  Albanis M.D.", "title": "Senior Vice President of Early Clinical & Translational Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew E. Mulberg CPI, FAAP, M.D.", "title": "Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ricardo  Jimenez", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arvind  Sreedharan", "title": "Senior Vice President of Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Jordan M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 18.77, "open": 18.75, "dayLow": 18.0856, "dayHigh": 19.97, "regularMarketPreviousClose": 18.77, "regularMarketOpen": 18.75, "regularMarketDayLow": 18.0856, "regularMarketDayHigh": 19.97, "forwardPE": -4.723077, "volume": 101818, "regularMarketVolume": 101818, "averageVolume": 387711, "averageVolume10days": 355520, "averageDailyVolume10Day": 355520, "bid": 14.02, "ask": 23.23, "bidSize": 200, "askSize": 200, "marketCap": 273623584, "fiftyTwoWeekLow": 14.42, "fiftyTwoWeekHigh": 74.49, "priceToSalesTrailing12Months": 295.80927, "fiftyDayAverage": 20.3981, "twoHundredDayAverage": 34.41695, "currency": "USD", "enterpriseValue": 147750032, "floatShares": 5285163, "sharesOutstanding": 14854700, "sharesShort": 2005059, "sharesShortPriorMonth": 1817476, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.135, "heldPercentInsiders": 0.09835, "heldPercentInstitutions": 1.09153, "shortRatio": 8.96, "shortPercentOfFloat": 0.1488, "impliedSharesOutstanding": 14854700, "bookValue": 10.561, "priceToBook": 1.744153, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -3276000, "trailingEps": -4.09, "forwardEps": -4.64, "lastSplitFactor": "1:4", "lastSplitDate": 1702944000, "enterpriseToRevenue": 159.73, "enterpriseToEbitda": -2.039, "52WeekChange": -0.37013423, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NGNE", "underlyingSymbol": "NGNE", "shortName": "Neurogene Inc.", "longName": "Neurogene Inc.", "firstTradeDateEpochUtc": 1394202600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "51d6a4c2-efb6-34ae-b4ed-f6ab994594b8", "messageBoardId": "finmb_602062523", "gmtOffSetMilliseconds": -18000000, "currentPrice": 18.42, "targetHighPrice": 72.0, "targetLowPrice": 45.0, "targetMeanPrice": 52.8, "targetMedianPrice": 46.0, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 138992992, "totalCashPerShare": 9.357, "ebitda": -72449000, "totalDebt": 13119000, "quickRatio": 8.84, "currentRatio": 9.092, "totalRevenue": 925000, "debtToEquity": 9.547, "revenuePerShare": 0.072, "returnOnAssets": -0.3975, "returnOnEquity": -0.5363, "grossProfits": -56729000, "freeCashflow": -35528876, "operatingCashflow": -70079000, "operatingMargins": -81.86595, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]